G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
TL;DR: It is advocated that OV-induced antiviral immune responses hold intrinsic anticancer benefits and are essential for establishing clinically desired antitumor immunity.
Book ChapterDOI
Implication of mitochondria in apoptosis
Patrice X. Petit,Naoufal Zamzami,Jean-Luc Vayssière,Bernard Mignotte,Guido Kroemer,Maria Castedo +5 more
TL;DR: Evidence is accumulating that cytoplasmic structures, including mitochondria, participate in the critical effector stage and that alterations usually considered to define apoptosis, as nuclear chromatolysis and cytolysis, have to be ascribed to the late degradation phase.
Journal ArticleDOI
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Lisa Derosa,Bertrand Routy,Andrew Maltez Thomas,Valerio Iebba,Gérard Zalcman,Sylvie Friard,Julien Mazieres,Clarisse Audigier-Valette,Denis Moro-Sibilot,François Goldwasser,Carolina Alves Costa Silva,Safae Terrisse,Mélodie Bonvalet,Arnaud Scherpereel,H. Pegliasco,Corentin Richard,François Ghiringhelli,Arielle Elkrief,Antoine Désilets,F. Blanc-Durand,Fabio Cumbo,Aitor Abuin Blanco,Romain Boidot,Sandy Chevrier,Romain Daillère,Guido Kroemer,Laurie Alla,Nicolas Pons,E. Le Chatelier,Nathalie Galleron,Hugo Roume,Agathe Dubuisson,M. Bouchard,Meriem Messaoudene,Damien Drubay,Eric Deutsch,Fabrice Barlesi,David Planchard,Nicola Segata,Stéphanie Martinez,Laurence Zitvogel,Jean-Charles Soria,Benjamin Besse +42 more
TL;DR: In this article , the authors performed shotgun-metagenomics-based microbiome profiling in a large cohort of patients with advanced NSCLC (n = 338) treated with first- or second-line ICIs to prospectively validate the predictive value of fecal Akk.
Journal ArticleDOI
Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
Daniela De Stefano,Valeria Rachela Villella,Speranza Esposito,Antonella Tosco,Angela Sepe,Fabiola De Gregorio,Laura Salvadori,R. Grassia,Carlo A Leone,Giuseppe De Rosa,Maria Chiara Maiuri,Massimo Pettoello-Mantovani,Stefano Guido,Anna Bossi,A. Zolin,Andrea Venerando,Lorenzo A. Pinna,Anil Mehta,Gianni Bona,Guido Kroemer,Luigi Maiuri,Valeria Raia +21 more
TL;DR: It is reported that oral treatment with cysteamine greatly reduces the mortality rate and improves the phenotype of newborn mice bearing the F508del-CFTR mutation, and optimal schedules of cysteamines plus EGCG might be used for the treatment of CF caused by the F504del- CFTR mutation.
Journal ArticleDOI
NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome
Thorsten Braun,Gabrielle Carvalho,Arnauld Coquelle,Marie-Catherine Vozenin,Pascale Lepelley,François Hirsch,Jean-Jacques Kiladjian,Vincent Ribrag,Pierre Fenaux,Guido Kroemer +9 more
TL;DR: It is postulate that NF-kappaB activation is responsible for the progressive suppression of apoptosis affecting differentiating MDS cells and thus contributes to malignant transformation.